As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.
|Original language||English (US)|
|Number of pages||6|
|Journal||Current opinion in rheumatology|
|State||Published - Sep 1 2008|
- Juvenile idiopathic arthritis
- Tumor necrosis tor
ASJC Scopus subject areas